1932
0
  1. Home
  2. A-Z Publications
  3. Annual Review of Medicine
  4. Volume 73, 2022
  5. Article

Annual Review of Medicine

Volume 73, 2022

Hypertrophic Cardiomyopathy: New Concepts and Therapies

Abstract

Hypertrophic cardiomyopathy (HCM), a relatively common, globally distributed, and often inherited myocardial disorder, transformed over the last several years into a treatable condition with the emergence of effective management options that alter natural history at all ages. Now available are a matured risk stratification algorithm selecting patients for prophylactic implantable defibrillators that prevent arrhythmic sudden death; low-risk, high-benefit surgical myectomy to reverse progressive heart failure symptoms due to left ventricular outflow obstruction; anticoagulation prophylaxis to prevent atrial fibrillation–mediated embolic stroke; and heart transplant for refractory end-stage disease in the absence of obstruction. Those strategies have resulted in reduction of HCM-related morbidity and reduction of mortality to 0.5% per year.

Keyword(s): atrial fibrillation, echocardiography, heart failure, hypertrophic cardiomyopathy, magnetic resonance, sudden death
Loading

Article metrics loading...

/content/journals/10.1146/annurev-med-042220-021539
2022-01-27
2024-12-07
Loading full text...

Full text loading...

/deliver/fulltext/med/73/1/annurev-med-042220-021539.html?itemId=/content/journals/10.1146/annurev-med-042220-021539&mimeType=html&fmt=ahah

Literature Cited

  1. 1. 
    Maron BJ. 2018.. Clinical course and management of hypertrophic cardiomyopathy. . N. Engl. J. Med. 379::655–68
     [Google Scholar]
  2. 2. 
    Maron BJ, Rowin EJ, Maron MS. 2018.. Global burden of hypertrophic cardiomyopathy. . JACC Heart Fail. 6::376–78
     [Google Scholar]
  3. 3. 
    Elliott PM, Anastasakis A, Borger MA, et al. 2014.. ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). . Eur. Heart J. 35::2733–79
     [Google Scholar]
  4. 4. 
    Gersh BJ, Maron BJ, Bonow RO, et al. 2011.. ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.. Circulation 124::2761–96
     [Google Scholar]
  5. 5. 
    Ommen SR, Mital S, Burke MA, et al. 2020.. AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy. . J. Am. Coll. Cardiol. 76::e159–e240
     [Google Scholar]
  6. 6. 
    Rowin EJ, Maron MS, Chan RH, et al. 2017.. Interaction of adverse disease-related pathways in hypertrophic cardiomyopathy. . Am. J. Cardiol. 120::2256–64
     [Google Scholar]
  7. 7. 
    Rowin EJ, Maron BJ, Haas TS, et al. 2017.. Hypertrophic cardiomyopathy with left ventricular apical aneurysm: implications for risk stratification and management. . J. Am. Coll. Cardiol. 69::761–73
     [Google Scholar]
  8. 8. 
    Rowin EJ, Maron BJ, Maron MS. 2020.. The hypertrophic cardiomyopathy phenotype viewed through the prism of multimodality imaging: clinical and etiologic implications. . JACC Cardiovasc. Imaging 13::2002–16
     [Google Scholar]
  9. 9. 
    Maron BJ, Maron MS, Rowin EJ. 2017.. Perspectives on the overall risks of living with hypertrophic cardiomyopathy. . Circulation 135::2317–19
     [Google Scholar]
  10. 10. 
    Maron MS, Rowin EJ, Wessler BS, et al. 2019.. Enhanced American College of Cardiology/American Heart Association strategy for prevention of sudden cardiac death in high risk patients with hypertrophic cardiomyopathy. . JAMA Cardiol. 4::644–57
     [Google Scholar]
  11. 11. 
    Maron BJ, Rowin EJ, Maron MS. 2021.. Evolution of risk stratification and sudden death prevention in hypertrophic cardiomyopathy: twenty years with the implantable cardioverter-defibrillator. . Heart Rhythm 18::1012–23
     [Google Scholar]
  12. 12. 
    Maron BJ, Spirito P, Shen WK, et al. 2007.. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. . JAMA 298::405–12
     [Google Scholar]
  13. 13. 
    Maron BJ, Rowin EJ, Casey SA, Maron MS. 2016.. How hypertrophic cardiomyopathy became a contemporary treatable genetic disease with low mortality: shaped by 50 years of clinical research and practice. . JAMA Cardiol. 1::98–105
     [Google Scholar]
  14. 14. 
    Maron BJ, Casey SA, Olivotto I, et al. 2018.. Clinical course and quality of life in high-risk patients with hypertrophic cardiomyopathy and implantable cardioverter-defibrillators. . Circ. Arrhythm. Electrophysiol. 11::e005820
     [Google Scholar]
  15. 15. 
    Kotkar KD, Said SM, Dearani JA, Schaff HV. 2017.. Hypertrophic obstructive cardiomyopathy: the Mayo Clinic experience. . Ann. Cardiothorac. Surg. 6::329–36
     [Google Scholar]
  16. 16. 
    Wells S, Rowin EJ, Bhatt V, et al. 2018.. Association between race and clinical profile of patients referred for hypertrophic cardiomyopathy. . Circulation 137::1973–75
     [Google Scholar]
  17. 17. 
    Eberly LA, Day SM, Ashley EA, et al. 2019.. Association of race with disease expression and clinical outcomes among patients with hypertrophic cardiomyopathy. . JAMA Cardiol. 5::83–91
     [Google Scholar]
  18. 18. 
    Maron BJ, Casey SA, Poliac LC, et al. 1999.. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. . JAMA 281::650–55
     [Google Scholar]
  19. 19. 
    Maron BJ, Gardin JM, Flack JM, et al. 1995.. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA study. . Circulation 92::785–89
     [Google Scholar]
  20. 20. 
    Semsarian C, Ingles J, Maron MS, Maron BJ. 2015.. New perspectives on the prevalence of hypertrophic cardiomyopathy. . J. Am. Coll. Cardiol. 65::1249–54
     [Google Scholar]
  21. 21. 
    Maron MS, Hellawell JL, Lucove JC, et al. 2016.. Occurrence of clinically diagnosed hypertrophic cardiomyopathy in the United States. . Am. J. Cardiol. 117::1651–54
     [Google Scholar]
  22. 22. 
    Cirino AL, Harris S, Lakdawala NK, et al. 2017.. Role of genetic testing in inherited cardiovascular disease: a review. . JAMA Cardiol. 2::1153–60
     [Google Scholar]
  23. 23. 
    Burke MA, Cook SA, Seidman JG, Seidman CE. 2016.. Clinical and mechanistic insights into the genetics of cardiomyopathy. . J. Am. Coll. Cardiol. 68::2871–86
     [Google Scholar]
  24. 24. 
    Maron BJ, Maron MS, Semsarian C. 2012.. Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. . J. Am. Coll. Cardiol. 60::705–15
     [Google Scholar]
  25. 25. 
    Maron BJ, Maron MS, Maron BA, Loscalzo J. 2019.. Moving beyond the sarcomere to explain heterogeneity in hypertrophic cardiomyopathy: JACC Review Topic of the Week. . J. Am. Coll. Cardiol. 73::1978–86
     [Google Scholar]
  26. 26. 
    Toepfer CN, Wakimoto H, Garfinkel AC, et al. 2019.. Hypertrophic cardiomyopathy mutations in MYBPC3 dysregulate myosin. . Sci. Transl. Med. 11:(476):eaat1199
     [Google Scholar]
  27. 27. 
    Toepfer CN, Garfinkel AC, Venturini G, et al. 2020.. Myosin sequestration regulates sarcomere function, cardiomyocyte energetics, and metabolism, informing the pathogenesis of hypertrophic cardiomyopathy. . Circulation 141::828–42
     [Google Scholar]
  28. 28. 
    Maron BJ, Maron MS, Maurer MS, et al. 2021.. Cardiovascular diseases that have emerged from the darkness. . J. Am. Heart Assoc. 10::e021095
     [Google Scholar]
  29. 29. 
    Maron BJ, Rowin EJ, Maron MS. 2020.. Hypertrophic cardiomyopathy: Is a “cure” coming…or is it already here?. Am. J. Med. 133::886–88
     [Google Scholar]
  30. 30. 
    Maron BA, Wang RS, Shevtsov S, et al. 2021.. Individualized interactomes for network-based precision medicine in hypertrophic cardiomyopathy with implications for other clinical pathophenotypes. . Nat. Commun. 12::873
     [Google Scholar]
  31. 31. 
    Rowin EJ, Maron BJ, Chokshi A, et al. 2018.. Clinical spectrum and management implications of left ventricular outflow obstruction with mild ventricular septal thickness in hypertrophic cardiomyopathy. . Am. J. Cardiol. 122::1409–20
     [Google Scholar]
  32. 32. 
    Chan RH, Maron BJ, Olivotto I, et al. 2014.. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. . Circulation 130::484–95
     [Google Scholar]
  33. 33. 
    Rowin EJ, Maron BJ, Carrick RT, et al. 2020.. Outcomes in patients with hypertrophic cardiomyopathy and left ventricular systolic dysfunction. . J. Am. Coll. Cardiol. 75::3033–43
     [Google Scholar]
  34. 34. 
    Vriesendorp PA, Schinkel AF, Van Cleemput J, et al. 2013.. Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy: patient outcomes, rate of appropriate and inappropriate interventions, and complications. . Am. Heart J. 166::496–502
     [Google Scholar]
  35. 35. 
    Schinkel AF, Vriesendorp PA, Sijbrands EJ, et al. 2012.. Outcome and complications after implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: systematic review and meta-analysis. . Circ. Heart Fail. 5::552–59
     [Google Scholar]
  36. 36. 
    Maron BJ, Rowin EJ, Casey SA, et al. 2015.. Hypertrophic cardiomyopathy in adulthood associated with low cardiovascular mortality with contemporary management strategies. . J. Am. Coll. Cardiol. 65::1915–28
     [Google Scholar]
  37. 37. 
    Maron BJ, Rowin EJ, Casey SA, et al. 2016.. Hypertrophic cardiomyopathy in children, adolescents, and young adults associated with low cardiovascular mortality with contemporary management strategies. . Circulation 133::62–73
     [Google Scholar]
  38. 38. 
    Maron BJ, Rowin EJ, Maron MS. 2019.. Paradigm of sudden death prevention in hypertrophic cardiomyopathy. . Circ. Res. 125::370–78
     [Google Scholar]
  39. 39. 
    Rowin EJ, Burrows A, Madias C, et al. 2020.. Long-term outcome in high-risk patients with hypertrophic cardiomyopathy after primary prevention defibrillator implants. . Circ. Arrhythm. Electrophysiol. 13::e008123
     [Google Scholar]
  40. 40. 
    Maron MS, Brush J, Rowin EJ, Maron BJ. 2021.. Back to the future: predicting sudden death in hypertrophic cardiomyopathy relying on individual risk markers and physician judgment without mathematical scoring. . Heart Rhythm 18::148–50
     [Google Scholar]
  41. 41. 
    Maron BJ, Rowin EJ, Casey SA, et al. 2013.. Risk stratification and outcome of patients with hypertrophic cardiomyopathy ≥60 years of age. . Circulation 127::585–93
     [Google Scholar]
  42. 42. 
    O'Mahony C, Jichi F, Ommen SR, et al. 2018.. International external validation study of the 2014 European Society of Cardiology Guidelines on sudden cardiac death prevention in hypertrophic cardiomyopathy (EVIDENCE-HCM). . Circulation 137::1015–23
     [Google Scholar]
  43. 43. 
    Lambiase PD, Gold MR, Hood M, et al. 2016.. Evaluation of subcutaneous ICD early performance in hypertrophic cardiomyopathy from the pooled EFFORTLESS and IDE cohorts. . Heart Rhythm 13::1066–74
     [Google Scholar]
  44. 44. 
    Maron BJ, Estes NAM. 2021.. The “Guidant Affair”: 15 years later. . Heart Rhythm 18::487–88
     [Google Scholar]
  45. 45. 
    Maron BJ, Haas TS, Ahluwalia A, et al. 2016.. Demographics and epidemiology of sudden deaths in young competitive athletes: from the United States National Registry. . Am. J. Med. 129::1170–77
     [Google Scholar]
  46. 46. 
    Maron BJ, Udelson JE, Bonow RO, et al. 2015.. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 3: hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy and other cardiomyopathies, and myocarditis. . J. Am. Coll. Cardiol. 66::2362–71
     [Google Scholar]
  47. 47. 
    Maron BJ. 2015.. Historical perspectives on sudden deaths in young athletes with evolution over 35 years. . Am. J. Cardiol. 116::1461–68
     [Google Scholar]
  48. 48. 
    Maron BJ. 2003.. Sudden death in young athletes. . N. Eng. J. Med. 349::1064–75
     [Google Scholar]
  49. 49. 
    Maron MS, Olivotto I, Zenovich AG, et al. 2006.. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. . Circulation 114::2232–39
     [Google Scholar]
  50. 50. 
    Ommen SR, Maron BJ, Olivotto I, et al. 2005.. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. . J. Am. Coll. Cardiol. 46::470–76
     [Google Scholar]
  51. 51. 
    Rastegar H, Boll G, Rowin EJ, et al. 2017.. Results of surgical septal myectomy for obstructive hypertrophic cardiomyopathy: the Tufts experience. . Ann. Cardiothorac. Surg. 6::353–63
     [Google Scholar]
  52. 52. 
    Desai MY, Bhonsale A, Smedira NG, et al. 2013.. Predictors of long-term outcomes in symptomatic hypertrophic obstructive cardiomyopathy patients undergoing surgical relief of left ventricular outflow tract obstruction. . Circulation 128::209–16
     [Google Scholar]
  53. 53. 
    Vanderlaan RD, Woo A, Ralph-Edwards A. 2017.. Isolated septal myectomy for hypertrophic obstructive cardiomyopathy: an update on the Toronto General Hospital experience. . Ann. Cardiothorac. Surg. 6::364–68
     [Google Scholar]
  54. 54. 
    Hodges K, Rivas CG, Aguilera J, et al. 2019.. Surgical management of left ventricular outflow tract obstruction in a specialized hypertrophic obstructive cardiomyopathy center. . J. Cardiovasc. Surg. 157::2289–99
     [Google Scholar]
  55. 55. 
    Ferrazzi P, Spirito P, Iacovoni A, et al. 2015.. Transaortic chordal cutting: mitral valve repair for obstructive hypertrophic cardiomyopathy with mild septal hypertrophy. . J. Am. Coll. Cardiol. 66::1687–96
     [Google Scholar]
  56. 56. 
    Maron BJ, Dearani JA, Ommen SR, et al. 2015.. Low operative mortality achieved with surgical septal myectomy: role of dedicated hypertrophic cardiomyopathy centers in the management of dynamic subaortic obstruction. . J. Am. Coll. Cardiol. 66::1307–8
     [Google Scholar]
  57. 57. 
    Vriesendorp PA, Liebregts M, Steggerda RC, et al. 2014.. Long-term outcomes after medical and invasive treatment in patients with hypertrophic cardiomyopathy. . JACC Heart Fail. 2::630–36
     [Google Scholar]
  58. 58. 
    Sorajja P. 2017.. Alcohol septal ablation for obstructive hypertrophic cardiomyopathy: a word of balance. . J. Am. Coll. Cardiol. 70::489–94
     [Google Scholar]
  59. 59. 
    Sherrid MV, Balaram S, Kim B, et al. 2016.. The mitral valve in obstructive hypertrophic cardiomyopathy: a test in context. . J. Am. Coll. Cardiol. 67::1846–58
     [Google Scholar]
  60. 60. 
    Maron BJ, McKenna WJ, Danielson GK, et al. 2003.. American College of Cardiology/European Society of Cardiology clinical expert consensus document of hypertrophic cardiomyopathy. . J. Am. Coll. Cardiol. 42::1687–713
     [Google Scholar]
  61. 61. 
    Rowin EJ, Maron BJ, Olivotto I, Maron MS. 2017.. Role of exercise testing in hypertrophic cardiomyopathy. . JACC Cardiovasc. Imaging 10::1374–86
     [Google Scholar]
  62. 62. 
    Sherrid MV, Shetty A, Winson G, et al. 2013.. Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with β-blockade or verapamil. . Circ. Heart Fail. 6::694–702
     [Google Scholar]
  63. 63. 
    Sherrid MV, Barac I, McKenna WJ, et al. 2005.. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. . J. Am. Coll. Cardiol. 45::1251–58
     [Google Scholar]
  64. 64. 
    Olivotto I, Oreziak A, Barriales-Villa R, et al. 2020.. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. . Lancet 396::759–69
     [Google Scholar]
  65. 65. 
    Saberi S, Cardim N, Yamani M, et al. 2021.. Mavacamten favorably impacts cardiac structure in obstructive hypertrophic cardiomyopathy: EXPLORER-HCM cardiac magnetic resonance substudy analysis. . Circulation 143::606–8
     [Google Scholar]
  66. 66. 
    Maron MS, Rowin EJ, Olivotto I, et al. 2016.. Contemporary natural history and management of nonobstructive hypertrophic cardiomyopathy. . J. Am. Coll. Cardiol. 67::1399–409
     [Google Scholar]
  67. 67. 
    Maron MS, Kalsmith BM, Udelson JE, et al. 2010.. Survival after cardiac transplantation in patients with hypertrophic cardiomyopathy. . Circ. Heart Fail. 3::574–79
     [Google Scholar]
  68. 68. 
    Rowin EJ, Hausvater A, Link MS, et al. 2017.. Clinical profile and consequences of atrial fibrillation in hypertrophic cardiomyopathy. . Circulation 136::2420–36
     [Google Scholar]
  69. 69. 
    Maron BJ, Olivotto I, Bellone P, et al. 2002.. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. . J. Am. Coll. Cardiol. 39::301–7
     [Google Scholar]
  70. 70. 
    Boll G, Rowin EJ, Maron BJ, et al. 2020.. Efficacy of combined Cox-Maze IV and ventricular septal myectomy for treatment of atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy. . Am. J. Cardiol. 125::120–26
     [Google Scholar]
  71. 71. 
    Carrick RT, Maron MS, Adler A, et al. 2021.. Development and validation of a clinical predictive model for identifying hypertrophic cardiomyopathy patients at risk for atrial fibrillation: the HCM-AF score. . Circ. Arrhythm. Electrophysiol. 14::e009796
     [Google Scholar]
  72. 72. 
    Maurizi N, Michels M, Rowin EJ, et al. 2019.. Clinical course and significance of hypertrophic cardiomyopathy without left ventricular hypertrophy. . Circulation 139::830–33
     [Google Scholar]
  73. 73. 
    Maron BJ, Roberts WC, Arad M, et al. 2009.. Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy. . JAMA 301::1253–59
     [Google Scholar]
  74. 74. 
    Shirani J, Aurshiya R, Elshaikh A, et al. 2021.. Low risk of hypertrophic cardiomyopathy implemented in a non-referral and regional community-based center. . Am. J. Cardiol. 142::130–35
     [Google Scholar]
  75. 75. 
    Maron BJ. 2015.. Importance and feasibility of creating hypertrophic cardiomyopathy centers in developing countries: the experience in India. . Am. J. Cardiol. 116::332–34
     [Google Scholar]
  76. 76. 
    Rowin EJ, Maron MS, Wells S, et al. 2019.. Impact of sex on clinical course and survival in the contemporary treatment era for hypertrophic cardiomyopathy. . J. Am. Heart Assoc. 8::e012041
     [Google Scholar]
/content/journals/10.1146/annurev-med-042220-021539
Loading
Hypertrophic Cardiomyopathy: New Concepts and Therapies
Annual Review of Medicine 73, 363 (2022); https://doi.org/10.1146/annurev-med-042220-021539
/content/journals/10.1146/annurev-med-042220-021539
/content/journals/10.1146/annurev-med-042220-021539
Loading

Data & Media loading...

  • Article Type: Review Article

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error